United States

Showing 51-56 of 56 grants

Title	Institution	Researcher	Program	Duration	Total Award Amount
Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Mitigate Diabetic Ketoacidosis Risk?	University of Texas Health Science Center at San Antonio	Muhammad Abdul-Ghani	Improving Lives	01-June-2019 to 31-December-2026	$1,573,835.31
Optimization of fast-acting venom insulins as therapeutic candidates for T1D	University of Utah	Helena Safavi	Improving Lives	01-September-2022 to 31-August-2026	$890,372.53
Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes	University of Washington	Ian De Boer	Improving Lives	01-September-2023 to 31-March-2028	$2,107,411.00
Discovering early diagnostic markers of cardiovascular disease risk with lipidomics in a 30-year longitudinal prospective type 1 diabetes cohort	University of Wisconsin-Madison (Board of Regents University of Wisconsin System)	Judith Simcox	Improving Lives	01-November-2022 to 04-May-2026	$799,988.63
Assess the antigenic profile in human T1D: from β-cell crinophagy to peripheral blood	Washington University	Xiaoxiao Wan	Cures	01-April-2022 to 31-March-2027	$750,000.00
Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D	Yale University	Alfonso Galderisi	Cures	01-February-2023 to 30-September-2026	$747,380.88